Director, U.S. Asset Lead, Oncology (GI Tumor & GIST) - Philadelphia, PA

GSK•Philadelphia, PA

34d•Onsite

About The Position

The Director, U.S. Asset Lead is responsible for representing the U.S. commercial perspective across the lifecycle of a GI tumor asset and an additional oncology asset, ensuring development, commercialization strategy, and launch planning are optimized for the U.S. market. This role serves as the primary U.S. commercial leader interfacing with the global asset team, providing strategic guidance on target product profile (TPP), market positioning, clinical development prioritization, and commercial readiness to maximize asset value. The Director will work cross-functionally with Global Development, Medical Affairs, Market Access, Commercial Strategy, Regulatory, Forecasting, and Business Insights to shape the development path and commercialization strategy. The role requires deep expertise in U.S. oncology market dynamics, competitive intelligence, payer landscape, and launch excellence, ensuring the U.S. perspective informs global decisions from early development through launch and lifecycle management.

Requirements

Bachelor’s degree in business, life sciences, healthcare, or related field.
10+ years of experience in the biopharmaceutical industry, with significant experience in oncology.
Experience supporting late-stage development, launch planning, or commercialization of oncology therapies.
Location: Must be able to work onsite - Monday through Friday.

Nice To Haves

Proven ability to influence global cross-functional teams in a matrix environment.
Demonstrated expertise in U.S. oncology market dynamics, particularly GI (and GIST) cancers
Marketing background
Pipeline experience
Sales experience

Responsibilities

U.S. Asset Strategy Leadership: Serve as the U.S. commercial lead for assigned oncology assets, ensuring the U.S. perspective is embedded in development and commercialization decisions.
Provide strategic input into TPP assumptions to ensure alignment with U.S. market needs.
Shape U.S. positioning strategy, value proposition, and differentiation relative to current and emerging competitors.
Translate U.S. market insights into actionable strategy for global development teams.
Clinical Development & Indication Strategy: Partner with Global Development and Medical teams to ensure clinical programs support future U.S. commercial success.
Provide commercial input into: Indication prioritization, Endpoint selection, Comparator strategy, Trial design considerations
Identify opportunities to optimize label potential and market access positioning.
U.S. Market Intelligence & Competitive Strategy: Lead or contribute to U.S. market landscape assessments, including: Disease epidemiology, Treatment paradigms, Competitive intelligence, Emerging modalities
Monitor evolving competitive pipelines across GI, GU, and related tumor types, translating insights into strategic implications.
Partner with Business Insights and Analytics to synthesize U.S. market signals into global decision making.
Forecasting & Business Case Development: Collaborate with forecasting teams to develop robust U.S. revenue forecasts and scenario planning.
Lead assessment of commercial opportunity, pricing potential, and market uptake dynamics.
Provide strategic input into investment decisions and lifecycle planning.
Commercial Launch Excellence: Lead early U.S. launch readiness in partnership with global and U.S. commercial teams.
Define core U.S. launch strategy, including: Customer segmentation, Positioning and messaging, Access strategy, Commercial model considerations
Ensure alignment across Sales, Marketing, Market Access, and Medical Affairs to enable successful launch execution.
Cross-Functional Leadership: Serve as a key integrator across: Global Asset Teams, U.S. Commercial Leadership, Medical Affairs, Market Access, Forecasting, Business Development
Drive alignment across stakeholders to ensure timely and strategic decision making.
External Engagement & Market Shaping: Engage with key opinion leaders (KOLs), advocacy groups, and clinical experts to inform development and commercial strategy.
Represent the company at major oncology congresses to gather insights and assess the competitive landscape.
Support efforts to shape treatment paradigms and standard-of-care evolution in relevant tumor types.